Sekisui to Buy Genzyme’s Test-Drug Operations For $265 Million
Sekisui Chemical Co. agreed to buy Genzyme Corp.’s test-drug operations for $265 million, according to a statement to the Tokyo Stock Exchange today.
To contact the reporter on this story: Go Onomitsu in Tokyo at email@example.com
To contact the editor responsible for this story: Kyung Bok Cho at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.